Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

Leijen, Suzanne; Middleton, Mark R; Tresca, Patricia; Kraeber-Bodéré, Françoise; Dieras, Veronique; Scheulen, Max E; Gupta, Avinash; Lopez-Valverde, Vanesa; Xu, Zhi-Xin; Rueger, Ruediger; Tessier, Jean J L; Shochat, Eliezer; Blotner, Steve; Naegelen, Valerie Meresse; Schellens, Jan H M; Eberhardt, Wilfried Ernst Erich

Leijen, Suzanne; Middleton, Mark R; Tresca, Patricia; Kraeber-Bodéré, Françoise; Dieras, Veronique; Scheulen, Max E; Gupta, Avinash; Lopez-Valverde, Vanesa; Xu, Zhi-Xin; Rueger, Ruediger; Tessier, Jean J L; Shochat, Eliezer; Blotner, Steve; Naegelen, Valerie Meresse; Schellens, Jan H M; Eberhardt, Wilfried Ernst Erich.

Affiliation

Leijen S; The Netherlands Cancer Institute, Amsterdam; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

Clin Cancer Res ; 18(17): 4794-805, 2012 Sep 01.

Article in En | MEDLINE | ID: mdl-22767668

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Oxazines / Benzamides / MAP Kinase Kinase Kinases / Protein Kinase Inhibitors / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2012 Document type: Article Affiliation country: Country of publication:

Search on Google

Add to My VHL

XML

PubMed Links